Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has proved helpful conscientiously but unsuccessfully to create a single therapy, variously called Pro 140, leronlimab, as well as Vyrologix.

In development of this therapy, CytoDyn has cast its net far and wide both geographically and in phrases of potential indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll actually be being used is an open question.

While CYDY  is actually dawdling, promote opportunities for leronlimab as being a combination treatment in the curing of multi-drug-resistant HIV happen to be closing.

I’m creating my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale of my past several shares. My 1st CytoDyn post, “CytoDyn: What to be able to Do When It’s Too Good In order to Be True?”, set away what follows prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan offered such an extremely promotional picture in the Uptick Newswire employment interview that I came away with a bad opinion of the business.

Irony of irony, the poor viewpoint of mine of the business has grown steadily, yet the disappointment has not been financial. 2 years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that gives a > six bagger at the moment still disappoints? Therein lies the story; allow me to explain.

CytoDyn acquired its much-storied therapy (which I shall refer to as leronlimab) back during 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor for your treatment as well as reduction of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti viral activity in HIV infected subjects. Today’s transaction of $3.5 huge number of transfers ownership of this know-how and also linked intellectual property coming from Progenics to CytoDyn, and also approximately 25 million mg of bulk drug substance…. milestone payments after commencement of a stage III clinical trial ($1.5 million) plus the very first brand new drug application endorsement ($five million), as well as royalty payments of five % of net sales after commercialization.

Since that point in time, CytoDyn’s leading nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition right into a springboard for CytoDyn to purchase a market place cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with many indications and many therapies, it has this single treatments and a “broad pipeline of indications” since it puts it. I call such pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a likely advantageous therapy of dozens of indications.

Its opening banner on its website (below) shows an energetic organization with diverse interests albeit focused on leronlimab, several illness types, multiple publications in addition to multiple delivering presentations.

Might it all be smoke cigarettes and mirrors? That is a question I have been asking myself through the really start of my interest in this particular organization. Judging by way of the multiples of a huge number of diverse comments on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I’m a lot from alone in this particular question.

CytoDyn is a traditional battleground, or possibly some may say cult inventory. Its adherents are fiercely shielding of the prospects of its, quick to label any negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *